

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,427 B2  
DATED : February 22, 2005  
INVENTOR(S) : Gerritsen et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [56], **References Cited**, FOREIGN PATENT DOCUMENTS, insert the following in appropriate order:

-- EP	1074617	02/2001
WO	WO 00/55332	09/2000
WO	WO 00/70028	11/2000
WO	WO 00/52173	09/2000
WO	WO 01/31029	05/2001 --.

OTHER PUBLICATIONS, insert the following in appropriate order:

-- Wilson, R.K., Nov. 27, 1996, GenBank Accession No. AA232646 --.  
"Orkin et al." reference, "Access the NIH Investment in Research on Gene Therapy, issued by the US National Institutes" should read -- Assess the NIH Investment in Research on Gene Therapy, issued by the US National Institutes --.

Column 3.

Line 27, "to an disorders" should read -- to disorders --.

Line 54, "SphK plypeptide," should read -- SphK polypeptide, --.

Column 4.

Line 35, "SEQ ID 0NO: 12);" should read -- SEQ ID NO: 12); --.

Column 5.

Line 57, "the fall length" should read -- the full length --.

Column 7.

Lines 35-36, "between nucleotides units" should read -- between nucleotide units --.

Column 8.

Line 28, "rabbit, dog, cat" should read -- rabbit, dog, cat, --.

Column 10.

Line 56, "may corresponds to" should read -- may correspond to --.

Column 16.

Line 4, "1119-11124." should read -- 1119-1124. --.

Column 21.

Line 52, "analogs homologs" should read -- analogs, homologs --.

Column 30.

Line 13, "antibodies, may" should read -- antibodies, may be --.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,427 B2  
DATED : February 22, 2005  
INVENTOR(S) : Gerritsen et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 52,

Line 60, "disorders (The disorders" should read -- disorders. The disorders --.

Column 54,

Line 14, "clinical trails" should read -- clinical trials --.

Column 60,

Line 41, "modifications considered" should read -- modifications are considered --.

Signed and Sealed this

Twenty-ninth Day of November, 2005

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized, with a large, looped initial "J" and a cursive "Dudas".

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*